Dataset: Expression Profiles of Breast Tumors from Singapore and Europe
To facilitate a better understanding of the molecular heterogeneity of breast cancer and to uncover gene-survival associations that...
To facilitate a better understanding of the molecular heterogeneity of breast cancer and to uncover gene-survival associations that segregate with distinct molecular subtypes, we recently compiled a meta-analytical database of over 2,000 human breast tumor expression profiles variously annotated for clinical and pathological variables and derived from various institutions worldwide. This database was utilized for the breast tumor study cited below: Nagalla, et. al., Genome Biology, 2013. While the majority of the tumor expression profiles included in this database derived from publicly accessible microarray repositories, a number of the samples had not been previously published. Here, we describe the origin of these samples and provide their associated clinical and pathological annotations with the hope that other investigators will be able to utilize these data in their own research. Breast tumor samples derived from the Institut Jules Bordet (IJB; Belgium), John Radcliffe Hospital (JRH; Oxford) and the National University Hospital (NUH, Singapore) were profiled on the Affymetrix U133A platform. The number of tumors profiled (n) and the corresponding dates of tumor diagnosis are as follows. IJB: n=41, 1994-2001; JRH: n=8, 1990-1993; and NUH: n=100, 2000-2002.
- Species:
- human
- Samples:
- 139
- Source:
- E-GEOD-45255
- Updated:
- Dec.12, 2014
- Registered:
- Jun.18, 2014
Sample | DMFS EVENT DEFINED AS DISTANT METASTASIS OR DEATH FROM BREAST CANCER | HER2 STATUS | PATIENT AGE | CHARACTERISTICS | HISTOLOGICAL GRADE | SIZE MM | TREATMENT TYPE | DFS TIME | DSS TIME | DMFS TIME | PGR STATUS | HISTOLOGY | YES | DSS EVENT DEFINED AS DEATH FROM BREAST CANCER | ER STATUS | DFS EVENT DEFINED AS ANY TYPE OF RECURRENCE OR DEATH FROM BREAST CANCER | LN STATUS |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSM1100175 | not specified | NA | 43 | endocrine? (0=no, 1=yes): 0 | G1 | 21 | none | 9.42 | NA | 9.419 | NA | NA | not specified | NA | ER+ | not specified | LN- |
GSM1100174 | not specified | NA | 37 | endocrine? (0=no, 1=yes): 0 | G2 | 23 | none | 10.61 | NA | 10.614 | NA | NA | not specified | NA | ER- | 1 | LN- |
GSM1100173 | 1 | NA | 67 | endocrine? (0=no, 1=yes): 0 | NA | 10 | none | 7.15 | NA | 7.151 | NA | NA | not specified | NA | ER- | 1 | LN- |
GSM1100172 | not specified | He- | 50 | endocrine? (0=no, 1=yes): 0 | G3 | 29 | CMFx6 | NA | 1.66027397260274 | 1.66 | PgR- | NA | 1 | not specified | ER- | NA | LN- |
GSM110017 | not specified | He- | 72 | endocrine? (0=no, 1=yes): 1 | G2 | 20 | tamoxifen | NA | 4.50958904109589 | 4.51 | PgR- | NA | 1 | not specified | ER+ | NA | LN- |
GSM1100170 | not specified | He+ | 56 | endocrine? (0=no, 1=yes): 1 | G1 | 30 | tamoxifen | NA | 3.92602739726027 | 3.93 | PgR+ | NA | 1 | not specified | ER+ | NA | LN- |
GSM1100169 | not specified | He- | 46 | endocrine? (0=no, 1=yes): 1 | G3 | 27 | CMFx6; Tamoxifen | NA | 4.95890410958904 | 4.96 | PgR- | NA | 1 | not specified | ER- | NA | LN- |
GSM1100168 | not specified | He+ | 45 | endocrine? (0=no, 1=yes): 1 | G2 | 30 | tamoxifen | NA | 4.56164383561644 | 4.56 | PgR+ | NA | 1 | not specified | ER+ | NA | LN- |
GSM1100167 | not specified | He+ | 48 | endocrine? (0=no, 1=yes): 0 | G3 | 60 | CMFx6 | NA | 5.00821917808219 | 5.01 | PgR- | NA | 1 | not specified | ER- | NA | LN- |
GSM1100166 | not specified | He- | 45 | endocrine? (0=no, 1=yes): 0 | G2 | 20 | CMFx6 | NA | 4.64383561643836 | 4.64 | PgR+ | NA | 1 | not specified | ER+ | NA | LN- |
GSM1100165 | not specified | He- | 70 | endocrine? (0=no, 1=yes): 1 | G2 | 20 | tamoxifen | NA | 5.13424657534247 | 5.13 | PgR- | NA | 1 | not specified | ER+ | NA | LN- |
GSM1100164 | not specified | NA | 59 | endocrine? (0=no, 1=yes): 0 | G3 | 45 | ACx4 | NA | 6.25753424657534 | 6.26 | PgR- | NA | 1 | not specified | ER- | NA | LN- |
GSM1100163 | not specified | He- | 61 | endocrine? (0=no, 1=yes): 1 | G3 | 14 | CMFx6; Arimidex/Tamoxifen | NA | 5.56712328767123 | 5.57 | PgR- | NA | 1 | not specified | ER- | NA | LN- |
GSM1100162 | not specified | He- | 60 | endocrine? (0=no, 1=yes): 1 | G3 | 20 | ACx4; Arimidex/Tamoxifen | NA | 5.10958904109589 | 5.11 | PgR+ | NA | 1 | not specified | ER+ | NA | LN- |
GSM110016 | not specified | He- | 53 | endocrine? (0=no, 1=yes): 1 | G3 | 19 | tamoxifen | NA | 5.52328767123288 | 5.52 | PgR+ | NA | 1 | not specified | ER+ | NA | LN- |
GSM1100160 | not specified | He- | 42 | endocrine? (0=no, 1=yes): 0 | G2 | 14 | CMFx6 | NA | 6.69315068493151 | 6.69 | PgR+ | NA | 1 | not specified | ER+ | NA | LN- |
GSM1100159 | not specified | He- | 73 | endocrine? (0=no, 1=yes): NA | NA | 38 | NA | NA | 6.18630136986301 | 6.19 | PgR- | NA | NA | not specified | ER- | NA | LN- |
GSM1100158 | not specified | NA | 46 | endocrine? (0=no, 1=yes): 1 | G3 | 32 | CMFx6; Tamoxifen | NA | 2.57260273972603 | 2.57 | NA | NA | 1 | not specified | NA | NA | LN- |
GSM1100157 | not specified | He+ | 57 | endocrine? (0=no, 1=yes): 1 | G1 | 20 | tamoxifen | NA | 3.11506849315069 | 3.12 | PgR- | NA | 1 | not specified | ER+ | NA | LN- |
GSM1100156 | not specified | He- | 66 | endocrine? (0=no, 1=yes): 1 | G1 | 27 | tamoxifen | NA | 5.93698630136986 | 5.94 | PgR+ | NA | 1 | not specified | ER+ | NA | LN- |
GSM1100155 | not specified | He+ | 62 | endocrine? (0=no, 1=yes): 1 | G3 | 27 | tamoxifen | NA | 6.12876712328767 | 6.13 | PgR+ | NA | 1 | not specified | ER+ | NA | LN- |
GSM1100154 | not specified | He- | 67 | endocrine? (0=no, 1=yes): 1 | G3 | 40 | ACx6; Tamoxifen | NA | 6.61369863013699 | 6.61 | PgR- | NA | 1 | not specified | ER- | NA | LN- |
GSM1100153 | not specified | He+ | 70 | endocrine? (0=no, 1=yes): 1 | G2 | 35 | tamoxifen | NA | 6.65205479452055 | 6.65 | PgR- | NA | 1 | not specified | ER+ | NA | LN- |
GSM1100152 | not specified | He+ | 77 | endocrine? (0=no, 1=yes): 1 | G2 | 15 | tamoxifen | NA | 6.17534246575342 | 6.18 | PgR+ | NA | 1 | not specified | ER+ | NA | LN- |
GSM110015 | not specified | He+ | 52 | endocrine? (0=no, 1=yes): 1 | G2 | 20 | ACx4; Tamoxifen | NA | 6.01917808219178 | 6.02 | PgR- | NA | 1 | not specified | ER- | NA | LN- |
GSM1100150 | not specified | He+ | 81 | endocrine? (0=no, 1=yes): 1 | G2 | 20 | tamoxifen | NA | 7.57260273972603 | 7.57 | PgR- | NA | 1 | not specified | ER+ | NA | LN- |
GSM1100149 | not specified | He- | 55 | endocrine? (0=no, 1=yes): 1 | G3 | 18 | tamoxifen | NA | 7.30684931506849 | 7.31 | PgR+ | NA | 1 | not specified | ER+ | NA | LN- |
GSM1100148 | not specified | He+ | 48 | endocrine? (0=no, 1=yes): 1 | G2 | 12 | Tamoxifen+Zoledronic acid | NA | 7.85479452054795 | 7.85 | NA | NA | 1 | not specified | ER+ | NA | LN- |
GSM1100147 | not specified | He- | 54 | endocrine? (0=no, 1=yes): 1 | G2 | 10 | tamoxifen | NA | 7.82191780821918 | 7.82 | PgR- | NA | 1 | not specified | ER- | NA | LN- |
GSM1100146 | 1 | He+ | 72 | endocrine? (0=no, 1=yes): 1 | G3 | 37 | Arimidex/Tamoxifen | NA | 5.16438356164384 | 3.30 | PgR+ | NA | 1 | not specified | ER+ | NA | LN- |
GSM1100145 | 1 | He- | 60 | endocrine? (0=no, 1=yes): 1 | G3 | 40 | CMFx2; Tamoxifen | NA | 6.75068493150685 | 3.65 | PgR+ | NA | 1 | not specified | ER+ | NA | LN- |
GSM1100144 | 1 | He- | 54 | endocrine? (0=no, 1=yes): 0 | G1 | 55 | ACx4 | NA | 8.02191780821918 | 6.15 | PgR- | NA | 1 | not specified | ER+ | NA | LN- |
GSM1100143 | 1 | He- | 36 | endocrine? (0=no, 1=yes): 1 | G2 | 13 | Tamoxifen+Zoledronic acid | NA | 7.07945205479452 | 2.42 | PgR- | NA | 1 | not specified | ER- | NA | LN- |
GSM1100142 | not specified | He- | 46 | endocrine? (0=no, 1=yes): 1 | G1 | 10 | Tamoxifen+Zoledronic acid | NA | 2.18904109589041 | 2.18 | PgR- | NA | 1 | not specified | ER+ | NA | LN- |
GSM110014 | 1 | He+ | 70 | endocrine? (0=no, 1=yes): 1 | G3 | 35 | tamoxifen | NA | 0.991780821917808 | 0.76 | PgR+ | NA | 1 | 1 | ER+ | NA | LN- |
GSM1100140 | 1 | He- | 73 | endocrine? (0=no, 1=yes): 0 | G3 | 34 | ACx3/CMFx1 | NA | 4.62191780821918 | 3.80 | PgR- | NA | 1 | 1 | ER- | NA | LN- |
GSM1100139 | 1 | He- | 63 | endocrine? (0=no, 1=yes): 1 | G3 | 46 | tamoxifen | NA | 4.92876712328767 | 2.21 | PgR+ | NA | 1 | 1 | ER+ | NA | LN- |
GSM1100138 | 1 | He- | 38 | endocrine? (0=no, 1=yes): 1 | G3 | 32 | ECx4; Tamoxifen | NA | 2.75342465753425 | 1.35 | PgR- | NA | 1 | 1 | ER+ | NA | LN- |
GSM1100137 | 1 | He+ | 57 | endocrine? (0=no, 1=yes): 1 | NA | 85 | tamoxifen | NA | 5.03561643835616 | 0.25 | PgR+ | NA | 1 | 1 | ER+ | NA | LN- |
GSM1100136 | 1 | He- | 68 | endocrine? (0=no, 1=yes): 1 | G3 | 17 | tamoxifen | NA | 6.17260273972603 | 4.51 | PgR+ | NA | 1 | 1 | ER+ | NA | LN- |
GSM1100135 | 1 | He- | 66 | endocrine? (0=no, 1=yes): 1 | G3 | 21 | tamoxifen | NA | 4.19452054794521 | 4.18 | PgR- | NA | 1 | 1 | ER- | NA | LN- |
GSM1100134 | 1 | He+ | 59 | endocrine? (0=no, 1=yes): 1 | G3 | 25 | tamoxifen | NA | 3.07945205479452 | 0.65 | PgR- | NA | 1 | 1 | ER- | NA | LN- |
GSM1100133 | 1 | He+ | 47 | endocrine? (0=no, 1=yes): 1 | G3 | 28 | CMFx6; Tamoxifen | NA | 2.12602739726027 | 1.39 | PgR+ | NA | 1 | 1 | ER+ | NA | LN- |
GSM1100132 | 1 | He+ | 63 | endocrine? (0=no, 1=yes): 1 | G2 | 30 | tamoxifen | NA | 3.44931506849315 | 3.05 | NA | NA | 1 | 1 | ER+ | NA | LN- |
GSM110013 | not specified | NA | 53 | endocrine? (0=no, 1=yes): 1 | G3 | 35 | Tam+CMFx6 cycles | 4.33 | 4.33 | 4.33 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN+ |
GSM1100130 | not specified | He- | 59 | endocrine? (0=no, 1=yes): NA | G1 | 60 | NA | 4.83 | 4.83 | 4.83 | PgR+ | invasive ductal carcinoma | NA | not specified | ER+ | not specified | LN+ |
GSM1100129 | not specified | He- | 62 | endocrine? (0=no, 1=yes): 1 | G3 | 20 | tamoxifen | 4.38 | 4.38 | 4.38 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100128 | not specified | He- | 43 | endocrine? (0=no, 1=yes): 1 | G1 | 24 | Tam+ACx4 cycles | 2.67 | 2.67 | 2.67 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN+ |
GSM1100127 | not specified | NA | 55 | endocrine? (0=no, 1=yes): 0 | G1 | 25 | none | 4.67 | 4.67 | 4.67 | NA | invasive ductal carcinoma and papillary carcinoma | not specified | not specified | NA | not specified | LN- |
GSM1100126 | not specified | He- | 84 | endocrine? (0=no, 1=yes): 1 | G3 | 28 | tamoxifen | 0.83 | 0.83 | 0.83 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100125 | 1 | He+ | 38 | endocrine? (0=no, 1=yes): 1 | G3 | 40 | Tam+AC | 2.00 | 2.00 | 2.00 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | 1 | LN+ |
GSM1100124 | not specified | He+ | 67 | endocrine? (0=no, 1=yes): 1 | G3 | 25 | tamoxifen | 4.92 | 4.92 | 4.92 | PgR- | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN+ |
GSM1100123 | not specified | He- | 52 | endocrine? (0=no, 1=yes): 1 | G1 | 20 | tamoxifen | 5.17 | 5.17 | 5.17 | PgR+ | invasive lobular carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100122 | 1 | He+ | 50 | endocrine? (0=no, 1=yes): 1 | G3 | 16 | Tam+ACx4 cycles | 3.83 | 5.75 | 3.83 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER- | 1 | LN+ |
GSM110012 | not specified | He+ | 64 | endocrine? (0=no, 1=yes): 1 | G3 | 50 | tamoxifen | 5.21 | 5.21 | 5.21 | PgR+ | medullary carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100120 | not specified | He- | 47 | endocrine? (0=no, 1=yes): 0 | G3 | 30 | CAF | 4.54 | 4.54 | 4.54 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN+ |
GSM1100119 | not specified | He+ | 38 | endocrine? (0=no, 1=yes): 1 | G3 | 38 | Tam+ACx4 cycles | 5.58 | 5.58 | 5.58 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100118 | not specified | He+ | 58 | endocrine? (0=no, 1=yes): 1 | G3 | 51 | Tam+ACx4 cycles | 5.92 | 5.92 | 5.92 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN+ |
GSM1100117 | not specified | He+ | 47 | endocrine? (0=no, 1=yes): 0 | G3 | 21 | ACx4 cycles | 5.88 | 5.88 | 5.88 | PgR- | invasive ductal carcinoma | 1 | not specified | ER- | not specified | LN- |
GSM1100116 | not specified | He- | 51 | endocrine? (0=no, 1=yes): 1 | G3 | 18 | Tam+CMFx6 cycles | 5.79 | 5.79 | 5.79 | PgR- | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100115 | not specified | He+ | 48 | endocrine? (0=no, 1=yes): 0 | G3 | 35 | ACx4 cycles | 5.83 | 5.83 | 5.83 | PgR- | invasive ductal carcinoma | 1 | not specified | ER- | not specified | LN- |
GSM1100114 | not specified | He- | 46 | endocrine? (0=no, 1=yes): 0 | G3 | 25 | ACx4 cycles | 5.83 | 5.83 | 5.83 | PgR- | invasive ductal carcinoma | 1 | not specified | ER- | not specified | LN- |
GSM1100113 | not specified | He+ | 51 | endocrine? (0=no, 1=yes): 0 | G3 | 27 | ACx4 cycles | 1.92 | 5.58 | 1.33 | PgR- | invasive ductal carcinoma | 1 | not specified | ER- | 1 | LN- |
GSM1100112 | not specified | He- | 36 | endocrine? (0=no, 1=yes): 1 | G3 | 25 | Tam+CMFx6 cycles | 6.17 | 6.17 | 6.17 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100 | not specified | He+ | 61 | endocrine? (0=no, 1=yes): 0 | G3 | 15 | CAFx6 cycles | 5.83 | 5.83 | 5.83 | PgR- | invasive ductal carcinoma | 1 | not specified | ER- | not specified | LN+ |
GSM1100110 | not specified | He+ | 48 | endocrine? (0=no, 1=yes): 0 | G3 | 32 | ACx4 cycles | 5.71 | 5.71 | 5.71 | PgR- | invasive ductal carcinoma | 1 | not specified | ER- | not specified | LN- |
GSM1100109 | not specified | He- | 61 | endocrine? (0=no, 1=yes): 0 | G3 | 25 | CMF | 5.88 | 5.88 | 5.88 | PgR- | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN+ |
GSM1100108 | not specified | He- | 42 | endocrine? (0=no, 1=yes): 0 | G3 | 20 | none | 1.17 | 6.50 | 1.17 | PgR- | medullary carcinoma | not specified | not specified | ER- | not specified | LN- |
GSM1100107 | not specified | He- | 77 | endocrine? (0=no, 1=yes): 1 | G1 | 40 | tamoxifen | 3.50 | 4.33 | 3.50 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100106 | NA | He- | 81 | endocrine? (0=no, 1=yes): 1 | G1 | 40 | tamoxifen | NA | NA | NA | PgR+ | papillary carcinoma | 1 | NA | ER+ | NA | LN- |
GSM1100105 | not specified | He+ | 42 | endocrine? (0=no, 1=yes): NA | G3 | 23 | NA | 4.00 | 4.00 | 4.00 | PgR- | invasive ductal carcinoma | NA | not specified | ER- | not specified | LN- |
GSM1100104 | 1 | He+ | 38 | endocrine? (0=no, 1=yes): 1 | G3 | 36 | Tam+ACx4 cycles | 2.29 | 2.88 | 2.29 | PgR- | invasive ductal carcinoma | 1 | not specified | ER+ | 1 | LN- |
GSM1100103 | 1 | He+ | 51 | endocrine? (0=no, 1=yes): 0 | G3 | 30 | ACx4 cycles | 0.79 | 1.46 | 0.79 | PgR- | invasive ductal carcinoma | 1 | not specified | ER- | 1 | LN+ |
GSM1100102 | not specified | He- | 60 | endocrine? (0=no, 1=yes): 1 | G1 | 15 | Tam+CMFx6 cycles | 5.58 | 5.79 | 5.58 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM110010 | not specified | He+ | 52 | endocrine? (0=no, 1=yes): 1 | G3 | 45 | Tam+ACx4 cycles | 6.29 | 6.29 | 6.29 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN+ |
GSM1100100 | not specified | He- | 48 | endocrine? (0=no, 1=yes): 0 | G3 | 35 | ACx4 cycles | 0.75 | 0.75 | 0.75 | PgR- | invasive ductal carcinoma | 1 | not specified | ER- | not specified | LN- |
GSM1100099 | not specified | He- | 42 | endocrine? (0=no, 1=yes): 0 | G3 | 22 | AC | 4.17 | 4.25 | 4.17 | PgR- | invasive ductal carcinoma | 1 | not specified | ER- | not specified | LN- |
GSM1100098 | not specified | He- | 48 | endocrine? (0=no, 1=yes): 0 | G3 | 30 | ACx4 cycles | 5.08 | 5.08 | 5.08 | PgR- | invasive ductal carcinoma | 1 | not specified | ER- | not specified | LN+ |
GSM1100097 | not specified | He+ | 34 | endocrine? (0=no, 1=yes): 0 | G3 | 35 | ACx8 cycles; taxol | 4.38 | 4.38 | 4.38 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN+ |
GSM1100096 | 1 | He- | 29 | endocrine? (0=no, 1=yes): 0 | G1 | 80 | CAFx6 cycles | 2.21 | 3.04 | 2.21 | PgR+ | invasive lobular carcinoma | 1 | 1 | ER+ | 1 | LN+ |
GSM1100095 | not specified | He- | 86 | endocrine? (0=no, 1=yes): 1 | G1 | 21 | tamoxifen | 3.13 | 4.38 | 3.13 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN+ |
GSM1100094 | 1 | He+ | 54 | endocrine? (0=no, 1=yes): 0 | G3 | 35 | CAF | 1.29 | 1.38 | 1.29 | PgR- | invasive ductal carcinoma | 1 | 1 | ER- | 1 | LN+ |
GSM1100093 | 1 | He+ | 46 | endocrine? (0=no, 1=yes): NA | G3 | 22 | NA | 0.13 | 0.38 | 0.13 | PgR- | invasive ductal carcinoma | NA | 1 | ER- | 1 | LN+ |
GSM1100092 | not specified | He- | 41 | endocrine? (0=no, 1=yes): 0 | G3 | 40 | ACx4 cycles | 5.54 | 5.54 | 5.54 | PgR- | invasive ductal carcinoma | 1 | not specified | ER- | not specified | LN- |
GSM110009 | 1 | He- | 80 | endocrine? (0=no, 1=yes): 1 | G3 | 40 | tamoxifen | 1.96 | 1.96 | 1.96 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | 1 | LN+ |
GSM1100090 | not specified | He+ | 45 | endocrine? (0=no, 1=yes): 0 | G3 | 20 | CAF | 4.83 | 4.83 | 4.83 | PgR- | invasive ductal carcinoma | 1 | not specified | ER- | not specified | LN+ |
GSM1100089 | not specified | He+ | 64 | endocrine? (0=no, 1=yes): 0 | G3 | 30 | ACx4 cycles | 5.08 | 5.08 | 5.08 | PgR- | invasive ductal carcinoma | 1 | not specified | ER- | not specified | LN- |
GSM1100088 | 1 | He+ | 62 | endocrine? (0=no, 1=yes): 0 | G3 | 35 | none | 0.88 | 1.00 | 0.88 | PgR- | invasive ductal carcinoma | not specified | not specified | ER- | 1 | LN+ |
GSM1100087 | 1 | He+ | 62 | endocrine? (0=no, 1=yes): 1 | G3 | 25 | Arimidex+CMFx2 cycles | 0.00 | 2.08 | 0.00 | PgR+ | invasive ductal carcinoma | 1 | 1 | ER+ | 1 | LN+ |
GSM1100086 | not specified | He+ | 58 | endocrine? (0=no, 1=yes): 0 | G3 | 30 | CAF | 1.96 | 1.96 | 1.96 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN+ |
GSM1100085 | not specified | He+ | 45 | endocrine? (0=no, 1=yes): 0 | G3 | 25 | AC | 5.25 | 5.29 | 5.25 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN+ |
GSM1100084 | 1 | He+ | 54 | endocrine? (0=no, 1=yes): 0 | G3 | 20 | ACx4 cycles | 3.96 | 4.63 | 3.96 | PgR- | invasive ductal carcinoma | 1 | 1 | ER- | 1 | LN+ |
GSM1100083 | not specified | NA | 44 | endocrine? (0=no, 1=yes): 0 | G3 | 50 | ACx4 cycles | 4.00 | 4.00 | 4.00 | PgR- | invasive ductal carcinoma | 1 | not specified | ER- | not specified | LN+ |
GSM1100082 | 1 | He+ | 74 | endocrine? (0=no, 1=yes): 1 | G3 | 30 | tamoxifen | 2.04 | 2.25 | 2.04 | PgR- | invasive ductal carcinoma | 1 | 1 | ER+ | 1 | LN+ |
GSM110008 | not specified | He+ | 52 | endocrine? (0=no, 1=yes): 0 | G3 | 35 | ACx4 cycles | 4.00 | 4.33 | 4.00 | PgR- | invasive lobular carcinoma | 1 | not specified | ER- | not specified | LN+ |
GSM1100080 | not specified | He+ | 55 | endocrine? (0=no, 1=yes): 0 | G3 | 60 | ACx4 cycles | 1.00 | 5.00 | 1.00 | PgR- | invasive ductal carcinoma | 1 | not specified | ER- | not specified | LN- |
GSM1100079 | not specified | He- | 66 | endocrine? (0=no, 1=yes): 1 | G1 | 38 | tamoxifen | NA | 0.13 | 0.13 | PgR+ | mucinous carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100078 | not specified | He- | 47 | endocrine? (0=no, 1=yes): 0 | G3 | 32 | CAF | 4.88 | 4.88 | 4.88 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN+ |
GSM1100077 | not specified | He+ | 55 | endocrine? (0=no, 1=yes): 1 | G3 | 20 | tamoxifen | 4.46 | 4.46 | 4.46 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100076 | not specified | He- | 45 | endocrine? (0=no, 1=yes): 1 | G1 | 15 | tamoxifen;goserelin | 5.46 | 5.46 | 5.46 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100075 | not specified | He+ | 34 | endocrine? (0=no, 1=yes): 0 | G3 | 40 | ACx4 cycles | 1.54 | 5.46 | 1.54 | PgR- | invasive ductal carcinoma | 1 | not specified | ER- | not specified | LN- |
GSM1100074 | not specified | He- | 47 | endocrine? (0=no, 1=yes): 0 | G2 | 35 | ACx4 cycles | 5.00 | 5.00 | 5.00 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100073 | not specified | He- | 49 | endocrine? (0=no, 1=yes): 1 | G2 | 15 | tamoxifen | 5.33 | 5.33 | 5.33 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100072 | not specified | He- | 64 | endocrine? (0=no, 1=yes): 1 | G2 | 12 | tamoxifen | 5.58 | 5.58 | 5.58 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM110007 | NA | He+ | 66 | endocrine? (0=no, 1=yes): NA | G2 | 17 | NA | NA | 0.08 | NA | PgR+ | invasive ductal carcinoma | NA | not specified | ER+ | NA | LN- |
GSM1100070 | not specified | He- | 46 | endocrine? (0=no, 1=yes): NA | G2 | 40 | NA | 4.00 | 4.50 | 4.00 | PgR+ | invasive ductal and lobular carcinoma | NA | not specified | ER- | not specified | LN+ |
GSM1100069 | not specified | He- | 73 | endocrine? (0=no, 1=yes): 1 | G2 | 20 | tamoxifen | 4.83 | 4.92 | 4.83 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN+ |
GSM1100068 | not specified | He- | 46 | endocrine? (0=no, 1=yes): 1 | G2 | 15 | Tam+CMFx6 cycles | 4.88 | 4.88 | 4.88 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100067 | not specified | He- | 42 | endocrine? (0=no, 1=yes): NA | G2 | 30 | NA | 4.50 | 4.50 | 4.50 | PgR- | invasive ductal carcinoma | NA | not specified | ER+ | not specified | LN+ |
GSM1100066 | 1 | He+ | 46 | endocrine? (0=no, 1=yes): 1 | G2 | 60 | Tam+CAFx2 cycles | 1.67 | 1.75 | 1.67 | PgR- | invasive ductal carcinoma | 1 | 1 | ER+ | 1 | LN+ |
GSM1100065 | not specified | He+ | 44 | endocrine? (0=no, 1=yes): 0 | G2 | 24 | none | 0.42 | 0.42 | 0.42 | PgR+ | invasive ductal carcinoma | not specified | not specified | ER+ | not specified | LN+ |
GSM1100064 | not specified | He- | 55 | endocrine? (0=no, 1=yes): 1 | G2 | 19 | tamoxifen | 4.92 | 4.92 | 4.92 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN+ |
GSM1100063 | not specified | He+ | 57 | endocrine? (0=no, 1=yes): 1 | G2 | 21 | tamoxifen | 4.75 | 4.75 | 4.75 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100062 | not specified | He- | 40 | endocrine? (0=no, 1=yes): 0 | G2 | 23 | CAF | 5.17 | 5.17 | 5.17 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN+ |
GSM110006 | not specified | He- | 44 | endocrine? (0=no, 1=yes): 0 | G2 | 35 | CMF | 4.67 | 4.67 | 4.67 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100060 | not specified | He+ | 46 | endocrine? (0=no, 1=yes): 0 | G2 | 30 | CAF | 5.67 | 5.67 | 5.67 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN+ |
GSM1100059 | not specified | He- | 35 | endocrine? (0=no, 1=yes): 1 | G2 | 40 | Tam+ACx4 cycles | 4.67 | 4.67 | 4.67 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER- | not specified | LN- |
GSM1100058 | not specified | He- | 55 | endocrine? (0=no, 1=yes): 0 | G2 | 15 | none | 1.25 | 4.58 | 0.67 | PgR+ | invasive ductal carcinoma | not specified | not specified | ER+ | 1 | LN- |
GSM1100057 | 1 | He+ | 67 | endocrine? (0=no, 1=yes): 0 | G2 | 25 | none | 2.83 | 2.83 | 2.83 | PgR- | invasive ductal carcinoma | not specified | not specified | ER- | 1 | LN- |
GSM1100056 | not specified | He+ | 75 | endocrine? (0=no, 1=yes): 1 | G2 | 40 | tamoxifen | 0.92 | 5.42 | 0.67 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER- | 1 | LN+ |
GSM1100055 | 1 | He- | 48 | endocrine? (0=no, 1=yes): 0 | G2 | 15 | anastrozole;taxol | 0.04 | 3.08 | 0.04 | PgR- | invasive lobular carcinoma | 1 | 1 | ER+ | 1 | LN- |
GSM1100054 | not specified | He+ | 49 | endocrine? (0=no, 1=yes): 1 | G2 | 23 | Tam+CAFx6 cycles | 5.25 | 5.25 | 5.25 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN+ |
GSM1100053 | not specified | He- | 69 | endocrine? (0=no, 1=yes): 0 | G2 | 25 | CAF | 5.00 | 5.00 | 5.00 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN+ |
GSM1100052 | NA | He+ | 51 | endocrine? (0=no, 1=yes): 1 | G2 | 25 | Tam+ACx8;taxol | NA | NA | NA | PgR- | invasive ductal carcinoma | 1 | NA | ER+ | NA | LN+ |
GSM110005 | not specified | He- | 60 | endocrine? (0=no, 1=yes): 1 | G2 | 20 | Tam+CMFx6 cycles | 6.33 | 6.33 | 6.33 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100050 | not specified | He+ | 77 | endocrine? (0=no, 1=yes): 1 | G2 | 35 | tamoxifen | 5.58 | 5.58 | 5.58 | PgR- | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100049 | not specified | He- | 53 | endocrine? (0=no, 1=yes): 0 | G2 | 22 | CMF | 5.75 | 5.92 | 5.75 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER- | not specified | LN+ |
GSM1100048 | not specified | He- | 50 | endocrine? (0=no, 1=yes): 0 | G2 | 25 | CAF | 5.83 | 5.83 | 5.83 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER- | not specified | LN+ |
GSM1100047 | not specified | He- | 52 | endocrine? (0=no, 1=yes): 0 | G2 | 18 | CMF | 5.79 | 5.79 | 5.79 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100046 | not specified | He- | 53 | endocrine? (0=no, 1=yes): 1 | G2 | 18 | tamoxifen | 6.00 | 6.00 | 6.00 | PgR- | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100045 | not specified | He+ | 46 | endocrine? (0=no, 1=yes): 0 | G2 | 15 | none | 4.04 | 4.08 | 4.04 | PgR- | invasive ductal carcinoma | not specified | not specified | ER- | not specified | LN- |
GSM1100044 | not specified | He+ | 48 | endocrine? (0=no, 1=yes): NA | G2 | 20 | NA | 5.63 | 5.63 | 5.63 | PgR+ | invasive ductal carcinoma | NA | not specified | ER+ | not specified | LN- |
GSM1100043 | 1 | He+ | 54 | endocrine? (0=no, 1=yes): 0 | G2 | 60 | ACx4 cycles | 2.00 | 2.25 | 2.00 | PgR- | invasive ductal carcinoma | 1 | not specified | ER- | 1 | LN+ |
GSM1100042 | not specified | He+ | 69 | endocrine? (0=no, 1=yes): 1 | G2 | 25 | tamoxifen | 6.25 | 6.25 | 6.25 | PgR- | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM110004 | not specified | He+ | 40 | endocrine? (0=no, 1=yes): 1 | G2 | 25 | Tam+CMFx6 cycles | 2.63 | 2.63 | 2.63 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100040 | not specified | He- | 69 | endocrine? (0=no, 1=yes): 1 | G2 | 35 | tamoxifen | 5.88 | 6.04 | 5.88 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100039 | not specified | He- | 69 | endocrine? (0=no, 1=yes): 1 | G2 | 30 | tamoxifen | 4.29 | 4.29 | 4.29 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |
GSM1100038 | 1 | He+ | 62 | endocrine? (0=no, 1=yes): 0 | G2 | 30 | ACx4 cycles | 1.13 | 1.13 | 1.13 | PgR- | invasive ductal carcinoma | 1 | not specified | ER- | 1 | LN+ |
GSM1100037 | not specified | He- | 41 | endocrine? (0=no, 1=yes): 1 | G2 | 20 | Tam+ACx4 cycles | 6.17 | 6.17 | 6.17 | PgR+ | invasive ductal carcinoma | 1 | not specified | ER+ | not specified | LN- |